m3taversal
a756745c18
- What: Converted 132 broken wiki links to plain text across 41 health domain files. Added Vida to the Active Agents table in CLAUDE.md. - Why: Leo's PR #15 review required these two changes before merge. - Details: Broken links were references to claims that don't yet exist (demand signals). Brackets removed so they read as plain text rather than broken links. Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
46 lines
4.2 KiB
Markdown
46 lines
4.2 KiB
Markdown
---
|
|
description: US healthcare spending projected to reach 8-10 trillion annually by 2035 from 4.9 trillion in 2025 as GLP-1 volume expansion gene therapy front-loading and new screening modalities overwhelm deflationary forces that only dominate post-2035
|
|
type: claim
|
|
domain: health
|
|
created: 2026-02-17
|
|
source: "Innovu chronic disease cost projection 2030; PwC future of health 2025; Stanford FSI NCD cost projection; American Heart Association CVD cost projection through 2035; KFF Medicare GLP-1 modeling"
|
|
confidence: likely
|
|
---
|
|
|
|
# the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline
|
|
|
|
The fundamental tension in healthcare economics: medicine can now cure diseases that were previously only manageable, but the cures are expensive and the newly treatable population is enormous. The transition period through ~2035 sees rising costs as new therapies launch at premium prices and reach expanding populations.
|
|
|
|
**Inflationary forces (dominant 2025-2035):**
|
|
- GLP-1 volume expansion vastly outpaces price compression -- chronic medication for 30-50 million Americans
|
|
- Multi-cancer early detection screening (MCED) finds more disease to treat -- annual blood tests for 100+ million adults over 50
|
|
- Gene therapy front-loading creates acute spending spikes at $500K-2M per treatment
|
|
- Personalized cancer vaccines require individualized manufacturing at $5-10B annually by 2035
|
|
- Continuous monitoring and AI-driven preventive care creates new intervention points ($10-20B annually)
|
|
- Chronic disease costs projected to reach $42 trillion by 2030 in the US
|
|
- Total US healthcare spending projected at $9 trillion annually by 2035
|
|
- Aging demographics compound all of the above
|
|
|
|
**Deflationary forces (emerging, dominant only post-2035):**
|
|
- Gene therapy cures eliminate lifetime chronic disease management costs
|
|
- GLP-1 generics and small molecules crash obesity drug prices (semaglutide patents expire ~2031-2032)
|
|
- Population-level obesity reduction decreases cardiovascular, diabetes, NASH, cancer burden
|
|
- AI-accelerated drug discovery reduces R&D costs by 40%, compressing time-to-generic
|
|
- Precision oncology reduces wasteful trial-and-error prescribing
|
|
- Earlier cancer detection shifts treatment from expensive late-stage to cheaper early-stage
|
|
|
|
The composition of spending shifts dramatically: less on chronic disease management (diabetes complications, repeat cardiovascular events, lifelong hemophilia factor), more on curative interventions (gene therapy, personalized vaccines), prevention (MCED screening, GLP-1s), and new care categories. Per-capita health outcomes improve substantially, but per-capita spending also increases. The deflationary equilibrium is real but 15-20 years away, not 5-10.
|
|
|
|
---
|
|
|
|
Relevant Notes:
|
|
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] -- the single largest inflationary driver
|
|
- [[gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment]] -- deflationary long-term but front-loaded spending in the transition
|
|
- [[personalized mRNA cancer vaccines show sustained 49 percent reduction in melanoma recurrence after five years representing a genuinely novel therapeutic paradigm]] -- new cost center from individualized manufacturing
|
|
- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] -- VBC is designed to bend the cost curve but faces these structural headwinds
|
|
- healthcare costs threaten to crowd out investment in humanitys future if the system is not restructured -- the macro consequence of an upward-bending cost curve
|
|
|
|
- launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds -- both healthcare costs and launch costs are keystone variables that gate entire industry ecosystems, but they move in opposite directions (healthcare bends up, launch bends down)
|
|
|
|
Topics:
|
|
- health and wellness
|